FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 337:1630-1631 November 27, 1997 Number 22 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Rand, J. H.

To the Editor: Although the antiphospholipid-antibody syndrome is defined clinically as thrombosis, thrombocytopenia, or pregnancy loss, with the presence of a positive test for antiphospholipid antibodies, the incidence of pregnancy disorders greatly exceeds the incidence of the other symptoms. Rand et al. (July 17 issue)¹ report that in their study, IgG fractions containing antiphospholipid antibodies prevented the formation of annexin V complexes on the surfaces of choriocarcinoma (BeWo) cells and primary trophoblast cells and increased the activation of coagulation by these cells. This mechanism may lead to thrombosis at the maternal–fetal interface, with damage to the placenta.

A common problem . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Heilmann, L., Tempelhoff, G.-F. v., Pollow, K. (2003). Antiphospholipid Syndrome in Obstetrics. CLIN APPL THROMB HEMOST 9: 143-150 [Abstract]